Over the past 12 months, $JANX has been mentioned 12 times across 2 distinct FinTwit voices, with the first mention appearing on July 25, 2025. The biotech sector voices have driven discussion of Janux Therapeutics, with @jacobplieth accounting for 11 of the 12 mentions and @adamfeuerstein contributing 1 mention. The most recent activity occurred on March 16, 2026, with mentions continuing through early 2026.

@jacobplieth has been the dominant voice discussing $JANX, often referencing the stock in comparative analysis with other biotech companies. Recent posts from March 2026 noted that $JANX declined 58% over a 12-month period while comparing its performance to other clinical-stage biotechs. The mentions span from initial coverage in late July 2025 through mid-March 2026, reflecting ongoing attention to the stock from biotech-focused voices.